Differential	O
protection	O
of	O
normal	B-cell_type
and	I-cell_type
malignant	I-cell_type
human	I-cell_type
myeloid	I-cell_type
progenitors	I-cell_type
(	O
CFU-GM	B-cell_type
)	O
from	O
Ara-C	O
toxicity	O
using	O
cycloheximide	O
.	O

Cycloheximide	O
,	O
a	O
reversible	O
protein	O
synthesis	O
inhibitor	O
,	O
is	O
thought	O
to	O
block	O
DNA	O
replication	O
in	O
normal	B-cell_type
cells	I-cell_type
by	O
preventing	O
synthesis	O
of	O
a	O
labile	B-protein
protein	I-protein
.	O

In	O
animal	O
systems	O
,	O
cycloheximide	O
protects	O
normal	B-cell_type
cells	I-cell_type
from	O
cytotoxic	O
S-phase	O
specific	O
agents	O
,	O
such	O
as	O
cytosine	O
arabinoside	O
(	O
Ara-C	O
)	O
.	O

Malignant	B-cell_type
cells	I-cell_type
appear	O
not	O
to	O
be	O
susceptible	O
to	O
cycloheximide-induced	O
cycle	O
arrest	O
and	O
,	O
subsequently	O
,	O
may	O
not	O
be	O
protected	O
from	O
Ara-C	O
cytotoxicity	O
.	O

The	O
effect	O
of	O
cycloheximide	O
on	O
granulocyte/macrophage	B-cell_type
progenitors	I-cell_type
(	O
CFU-GM	B-cell_type
)	O
after	O
in	O
vitro	O
Ara-C	O
exposure	O
was	O
examined	O
using	O
normal	O
human	O
bone	O
marrow	O
,	O
malignant	B-cell_type
progenitors	I-cell_type
from	O
patients	O
with	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
,	O
and	O
clonogenic	B-cell_line
cells	I-cell_line
from	O
the	O
human	B-cell_line
acute	I-cell_line
nonlymphocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
HL-60	I-cell_line
and	I-cell_line
KG-1	I-cell_line
.	O

Mononuclear	B-cell_line
or	I-cell_line
clonogenic	I-cell_line
cells	I-cell_line
were	O
incubated	O
for	O
one	O
hour	O
with	O
cycloheximide	O
,	O
followed	O
by	O
the	O
addition	O
,	O
for	O
three	O
or	O
17	O
hours	O
,	O
of	O
Ara-C	O
before	O
being	O
plated	O
in	O
a	O
methylcellulose	O
culture	O
system	O
.	O

CFU-GM	O
survival	O
was	O
significantly	O
increase	O
if	O
normal	O
cells	O
were	O
treated	O
with	O
cycloheximide	O
before	O
Ara-C	O
exposure	O
.	O

Similar	O
cycloheximide	O
pretreatment	O
of	O
CML	B-cell_type
progenitors	I-cell_type
and	O
clonogenic	B-cell_line
HL-60	I-cell_line
and	I-cell_line
KG-1	I-cell_line
cells	I-cell_line
failed	O
to	O
protect	O
CFU-GM	B-cell_type
from	O
Ara-C-induced	O
cytotoxicity	O
.	O

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

Differential	NULL
Protection	NULL
of	NULL
Normal	NULL
and	NULL
Malignant	NULL
Human	NULL
Myeloid	NULL
Progenitors	NULL
(	NULL
CFU-GM	NULL
)	NULL
From	NULL
Ara-C	NULL
Toxicity	NULL
Using	NULL
Cycloheximide	NULL
By	NULL
Christopher	NULL
A.	NULL
Slapak	NULL
,	NULL
Robert	NULL
L.	NULL
Fine	NULL
,	NULL
and	NULL
Carol	NULL
M.	NULL
Richman	NULL
Cycloheximide	NULL
,	NULL
a	NULL
reversible	NULL
protein	NULL
synthesis	NULL
inhibitor	NULL
,	NULL
is	NULL
thought	NULL
to	NULL
block	NULL
DNA	NULL
replication	NULL
in	NULL
normal	NULL
cells	NULL
by	NULL
preventing	NULL
synthesis	NULL
of	NULL
a	NULL
labile	NULL
protein	NULL
.	NULL

In	NULL
animal	NULL
systems	NULL
,	NULL
cycloheximide	NULL
protects	NULL
normal	NULL
cells	NULL
from	NULL
cytotoxic	NULL
S-phase	NULL
specific	NULL
agents	NULL
,	NULL
such	NULL
as	NULL
cytosine	NULL
arabinoside	NULL
(	NULL
Ara-C	NULL
)	NULL
.	NULL

Malignant	NULL
cells	NULL
appear	NULL
not	NULL
to	NULL
be	NULL
susceptible	NULL
to	NULL
cycloheximide-induced	NULL
cycle	NULL
arrest	NULL
and	NULL
,	NULL
subsequently	NULL
,	NULL
may	NULL
not	NULL
be	NULL
protected	NULL
from	NULL
Ara-C	NULL
cytotoxicity	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
cycloheximide	NULL
on	NULL
granulocyte/macrophage	NULL
progenitors	NULL
(	NULL
CFU-GM	NULL
)	NULL
after	NULL
in	NULL
vitro	NULL
Ara-C	NULL
exposure	NULL
was	NULL
examined	NULL
using	NULL
normal	NULL
human	NULL
bone	NULL
marrow	NULL
,	NULL
malignant	NULL
progenitors	NULL
from	NULL
patients	NULL
with	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
(	NULL
CML	NULL
)	NULL
,	NULL
FFECTIVE	NULL
TREATMENT	NULL
of	NULL
nonlymphocytic	NULL
leukemia	NULL
is	NULL
limited	NULL
by	NULL
the	NULL
lack	NULL
of	NULL
cytotoxic	NULL
drug	NULL
specificity	NULL
for	NULL
neoplastic	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Chemotherapy	NULL
destroys	NULL
normal	NULL
as	NULL
well	NULL
as	NULL
malignant	NULL
progenitors	NULL
,	NULL
leading	NULL
to	NULL
severe	NULL
myelosuppression	NULL
.	NULL

Attempts	NULL
to	NULL
improve	NULL
the	NULL
therapeutic	NULL
index	NULL
of	NULL
drugs	NULL
used	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
acute	NULL
leukemia	NULL
by	NULL
manipulating	NULL
cell	NULL
cycle	NULL
kinetics	NULL
(	NULL
eg	NULL
,	NULL
cell	NULL
synchronization	NULL
or	NULL
recruitment	NULL
)	NULL
have	NULL
not	NULL
been	NULL
consistently	NULL
more	NULL
effective	NULL
than	NULL
empirically	NULL
designed	NULL
treatment	NULL
protocols	NULL
.	NULL
``	NULL

Cycloheximide	NULL
and	NULL
other	NULL
reversible	NULL
protein	NULL
synthesis	NULL
inhibitors	NULL
have	NULL
been	NULL
shown	NULL
in	NULL
animal	NULL
systems	NULL
to	NULL
protect	NULL
normal	NULL
epithelial	NULL
and	NULL
bone	NULL
marrow	NULL
cells	NULL
from	NULL
S-phase	NULL
specific	NULL
cytotoxic	NULL
agents	NULL
,	NULL
such	NULL
as	NULL
cytosine	NULL
arabinoside	NULL
(	NULL
Ara-C	NULL
)	NULL
.	NULL

In	NULL
normal	NULL
cells	NULL
,	NULL
synthesis	NULL
of	NULL
a	NULL
labile	NULL
protein	NULL
is	NULL
necessary	NULL
for	NULL
DNA	NULL
synthesis	NULL
to	NULL
proceed	NULL
.	NULL
``	NULL

Inhibition	NULL
of	NULL
protein	NULL
synthesis	NULL
prevents	NULL
DNA	NULL
synthesis	NULL
and	NULL
therefore	NULL
diminishes	NULL
Ara-C	NULL
toxicity	NULL
.	NULL

In	NULL
transformed	NULL
cells	NULL
,	NULL
DNA	NULL
replication	NULL
appears	NULL
to	NULL
be	NULL
independent	NULL
of	NULL
protein	NULL
synthesis	NULL
.	NULL
``	NULL

Thus	NULL
,	NULL
cycloheximide	NULL
could	NULL
potentially	NULL
affect	NULL
a	NULL
differential	NULL
protection	NULL
of	NULL
normal	NULL
v	NULL
malignant	NULL
cells	NULL
from	NULL
phase-specific	NULL
cytotoxic	NULL
drugs	NULL
.	NULL

To	NULL
evaluate	NULL
this	NULL
hypothesis	NULL
in	NULL
a	NULL
human	NULL
myelopoietic	NULL
system	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
cycloheximide	NULL
on	NULL
the	NULL
in	NULL
vitro	NULL
cytotoxicity	NULL
of	NULL
Ara-C	NULL
on	NULL
normal	NULL
granulocyte/macrophage	NULL
progenitors	NULL
(	NULL
CFU-GM	NULL
)	NULL
,	NULL
on	NULL
malignant	NULL
progenitors	NULL
from	NULL
patients	NULL
with	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
(	NULL
CML	NULL
)	NULL
,	NULL
and	NULL
on	NULL
clonogenic	NULL
cells	NULL
from	NULL
human	NULL
acute	NULL
nonlymphocytic	NULL
leukemia	NULL
cells	NULL
lines	NULL
HL-60	NULL
and	NULL
KG-1	NULL
.	NULL

``	NULL
~'*	NULL
MATERIALS	NULL
AND	NULL
METHODS	NULL
Normal	NULL
bone	NULL
marrow	NULL
samples	NULL
were	NULL
collected	NULL
from	NULL
paid	NULL
adult	NULL
volunteers	NULL
after	NULL
obtaining	NULL
written	NULL
informed	NULL
consent	NULL
.	NULL

Peripheral	NULL
From	NULL
the	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
Chicago	NULL
and	NULL
Rush	NULL
Medical	NULL
College	NULL
,	NULL
Chicago	NULL
.	NULL

Supported	NULL
in	NULL
part	NULL
by	NULL
the	NULL
American	NULL
Cancer	NULL
Society	NULL
(	NULL
CH90	NULL
)	NULL
,	NULL
Leukemia	NULL
Research	NULL
Foundation	NULL
Grant	NULL
No	NULL
.	NULL

CA	NULL
27476	NULL
from	NULL
the	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
and	NULL
the	NULL
Dr	NULL
Louis	NULL
Sklarow	NULL
Memorial	NULL
Fund	NULL
.	NULL

Submitted	NULL
Dec	NULL
4	NULL
,	NULL
1984	NULL
;	NULL
accepted	NULL
April	NULL
2	NULL
,	NULL
1985	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Dr	NULL
Carol	NULL
M.	NULL
Richman	NULL
,	NULL
Section	NULL
of	NULL
Hematology	NULL
(	NULL
Jelke	NULL
371	NULL
)	NULL
,	NULL
Rush	NULL
Medical	NULL
Center	NULL
,	NULL
1753	NULL
W	NULL
Congress	NULL
Pkwy	NULL
,	NULL
Chicago	NULL
,	NULL
IL	NULL
60612	NULL
.	NULL

©	NULL
1985	NULL
by	NULL
Grune	NULL
&	NULL
Stratton	NULL
,	NULL
Inc.	NULL
0006-497	NULL
1/8	NULL
5/6604-00	NULL
1	NULL
4803.00/0	NULL
830	NULL
and	NULL
clonogenic	NULL
cells	NULL
from	NULL
the	NULL
human	NULL
acute	NULL
nonlymphocytic	NULL
leukemia	NULL
cell	NULL
lines	NULL
HL-60	NULL
and	NULL
KG-1	NULL
.	NULL

Mononuclear	NULL
or	NULL
clonogenic	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
one	NULL
hour	NULL
with	NULL
cyciohexi-mide	NULL
,	NULL
followed	NULL
by	NULL
the	NULL
addition	NULL
,	NULL
for	NULL
three	NULL
or	NULL
17	NULL
hours	NULL
,	NULL
of	NULL
Ara-C	NULL
before	NULL
being	NULL
plated	NULL
in	NULL
a	NULL
methylcellulose	NULL
culture	NULL
system	NULL
.	NULL

CFU-GM	NULL
survival	NULL
was	NULL
significantly	NULL
increased	NULL
if	NULL
normal	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
cycloheximide	NULL
before	NULL
Ara-C	NULL
exposure	NULL
.	NULL

Similar	NULL
cycloheximide	NULL
pretreatment	NULL
of	NULL
CML	NULL
progenitors	NULL
and	NULL
clonogenic	NULL
HL-60	NULL
and	NULL
KG-1	NULL
cells	NULL
failed	NULL
to	NULL
protect	NULL
CFU-GM	NULL
from	NULL
Ara-C-induced	NULL
cytotoxicity	NULL
.	NULL

©	NULL
1985	NULL
by	NULL
Grune	NULL
&	NULL
Stratton	NULL
,	NULL
Inc.	NULL
blood	NULL
samples	NULL
from	NULL
patients	NULL
with	NULL
Philadelphia	NULL
chromosome-positive	NULL
CML	NULL
in	NULL
the	NULL
stable	NULL
chronic	NULL
phase	NULL
were	NULL
obtained	NULL
during	NULL
routine	NULL
clinical	NULL
evaluations	NULL
.	NULL

All	NULL
patients	NULL
were	NULL
untreated	NULL
at	NULL
the	NULL
time	NULL
of	NULL
study	NULL
.	NULL

Heparinized	NULL
bone	NULL
marrow	NULL
aspirates	NULL
were	NULL
separated	NULL
on	NULL
Ficoll-Hypaque	NULL
density	NULL
gradients	NULL
(	NULL
S.G.	NULL
1.077	NULL
)	NULL
to	NULL
obtain	NULL
mononuclear	NULL
cells	NULL
for	NULL
study	NULL
.	NULL
``	NULL

''	NULL
In	NULL
patients	NULL
with	NULL
CML	NULL
,	NULL
fresh	NULL
(	NULL
two	NULL
patients	NULL
)	NULL
or	NULL
eryopre-served	NULL
(	NULL
seven	NULL
patients	NULL
)	NULL
mononuclear	NULL
cells	NULL
obtained	NULL
by	NULL
leukapheresis	NULL
were	NULL
used	NULL
instead	NULL
of	NULL
Ficoli-Hypaque-separated	NULL
cells	NULL
.	NULL
``	NULL

The	NULL
cryopreserved	NULL
cells	NULL
had	NULL
been	NULL
frozen	NULL
in	NULL
10	NULL
%	NULL
dimethylsulfoxide	NULL
and	NULL
20	NULL
%	NULL
autologous	NULL
plasma	NULL
using	NULL
a	NULL
controlled	NULL
rate	NULL
of	NULL
-	NULL
1	NULL
°C/per	NULL
minute	NULL
and	NULL
were	NULL
stored	NULL
in	NULL
the	NULL
low	NULL
vapor	NULL
phase	NULL
of	NULL
liquid	NULL
nitrogen	NULL
(	NULL
approximately	NULL
-150	NULL
°C	NULL
)	NULL
.	NULL
``	NULL

Vials	NULL
of	NULL
cryopreserved	NULL
cells	NULL
were	NULL
thawed	NULL
rapidly	NULL
at	NULL
37	NULL
°C	NULL
and	NULL
diluted	NULL
tenfold	NULL
over	NULL
ten	NULL
minutes	NULL
and	NULL
then	NULL
rapidly	NULL
diluted	NULL
to	NULL
the	NULL
appropriate	NULL
cell	NULL
concentration	NULL
before	NULL
drug	NULL
incubation	NULL
.	NULL

HL-60	NULL
and	NULL
KG-1	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
suspension	NULL
culture	NULL
using	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
15	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
Flow	NULL
Laboratories	NULL
,	NULL
Bethesda	NULL
,	NULL
Md	NULL
)	NULL
and	NULL
were	NULL
routinely	NULL
subcultured	NULL
every	NULL
seven	NULL
days	NULL
.	NULL

To	NULL
ensure	NULL
log	NULL
phase	NULL
growth	NULL
,	NULL
cells	NULL
were	NULL
also	NULL
subcultured	NULL
72	NULL
hours	NULL
before	NULL
each	NULL
study	NULL
.	NULL

'*	NULL
``	NULL
*	NULL
Cycloheximide	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co	NULL
,	NULL
St	NULL
Louis	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
mononuclear	NULL
cell	NULL
suspensions	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
1	NULL
or	NULL
10	NULL
ug/ml	NULL
.	NULL

Ara-C	NULL
(	NULL
Upjohn	NULL
Co	NULL
,	NULL
Kalamazoo	NULL
,	NULL
Mich	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
cell	NULL
suspensions	NULL
one	NULL
hour	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
cycloheximide	NULL
in	NULL
final	NULL
Ara-C	NULL
concentrations	NULL
of	NULL
1	NULL
or	NULL
10	NULL
ug/mL	NULL
.	NULL

Fresh	NULL
solutions	NULL
of	NULL
cycloheximide	NULL
and	NULL
Ara-C	NULL
were	NULL
prepared	NULL
for	NULL
each	NULL
experiment	NULL
.	NULL

Mononuclear	NULL
cells	NULL
(	NULL
10°/mL	NULL
)	NULL
from	NULL
normals	NULL
,	NULL
patients	NULL
with	NULL
CML	NULL
,	NULL
HL-60	NULL
,	NULL
or	NULL
KG-1	NULL
cells	NULL
were	NULL
incubated	NULL
at	NULL
37	NULL
°C	NULL
,	NULL
10	NULL
%	NULL
CO	NULL
,	NULL
;	NULL
/air	NULL
for	NULL
four	NULL
to	NULL
18	NULL
hours	NULL
in	NULL
Alpha	NULL
medium	NULL
(	NULL
Flow	NULL
)	NULL
containing	NULL
20	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

Four	NULL
sets	NULL
of	NULL
cell	NULL
suspensions	NULL
were	NULL
prepared	NULL
for	NULL
each	NULL
incubation	NULL
time	NULL
:	NULL
medium	NULL
alone	NULL
,	NULL
cycloheximide	NULL
alone	NULL
,	NULL
Ara-C	NULL
alone	NULL
(	NULL
three	NULL
or	NULL
17	NULL
hours	NULL
)	NULL
,	NULL
and	NULL
one	NULL
hour	NULL
of	NULL
cycloheximide	NULL
,	NULL
followed	NULL
by	NULL
incubation	NULL
with	NULL
Ara-C	NULL
for	NULL
three	NULL
or	NULL
17	NULL
hours	NULL
.	NULL

In	NULL
all	NULL
experiments	NULL
,	NULL
cycloheximide	NULL
remained	NULL
in	NULL
the	NULL
suspension	NULL
culture	NULL
during	NULL
Ara-C	NULL
exposure	NULL
.	NULL

In	NULL
three	NULL
experiments	NULL
,	NULL
cycloheximide	NULL
and	NULL
Ara-C	NULL
were	NULL
added	NULL
simultaneously	NULL
for	NULL
a	NULL
three-hour	NULL
incubation	NULL
.	NULL

After	NULL
incubation	NULL
,	NULL
each	NULL
cell	NULL
suspension	NULL
was	NULL
washed	NULL
three	NULL
times	NULL
and	NULL
plated	NULL
in	NULL
quadruplicate	NULL
using	NULL
a	NULL
methylcellulose	NULL
culture	NULL
system	NULL
at	NULL
final	NULL
concentrations	NULL
of	NULL
1	NULL
x	NULL
10°	NULL
cells	NULL
per	NULL
milliliter	NULL
for	NULL
normal	NULL
bone	NULL
marrow	NULL
,	NULL
1	NULL
to	NULL
2	NULL
x	NULL
10'/mL	NULL
for	NULL
CML	NULL
samples	NULL
,	NULL
2	NULL
x	NULL
10	NULL
%	NULL
/mL	NULL
for	NULL
HL-60	NULL
,	NULL
and	NULL
2	NULL
x	NULL
10*/mL	NULL
for	NULL
KG-1	NULL
cells	NULL
.	NULL

'*	NULL
``	NULL
Phytohemagglutinin-stimulated	NULL
leukocyte	NULL
conditioned	NULL
medium	NULL
was	NULL
the	NULL
source	NULL
of	NULL
colony-stimulating	NULL
activity	NULL
.	NULL
``	NULL

After	NULL
14	NULL
days	NULL
of	NULL
incubation	NULL
at	NULL
37	NULL
°C	NULL
in	NULL
a	NULL
10	NULL
%	NULL
humidified	NULL
CO	NULL
;	NULL
atmosphere	NULL
,	NULL
colonies	NULL
of	NULL
more	NULL
than	NULL
20	NULL
cells	NULL
(	NULL
representing	NULL
CFU-GM	NULL
)	NULL
were	NULL
counted	NULL
using	NULL
an	NULL
inverted	NULL
microscope	NULL
at	NULL
50x	NULL
magnification	NULL
.	NULL

Wright-stained	NULL
cytocen-trifuge	NULL
preparations	NULL
of	NULL
individual	NULL
colonies	NULL
from	NULL
normals	NULL
reveal	NULL
maturing	NULL
granulocytes	NULL
or	NULL
macrophages	NULL
or	NULL
both	NULL
using	NULL
this	NULL
culture	NULL
technique	NULL
.	NULL
'	NULL

''	NULL
All	NULL
results	NULL
were	NULL
expressed	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
controls	NULL
incubated	NULL
without	NULL
Ara-C	NULL
or	NULL
cycloheximide	NULL
.	NULL

The	NULL
mean	NULL
+	NULL
SE	NULL
of	NULL
the	NULL
Blood	NULL
,	NULL
Vol	NULL
66	NULL
,	NULL
No	NULL
4	NULL
(	NULL
October	NULL
)	NULL
,	NULL
1985	NULL
:	NULL
pp	NULL
830-834	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

CYCLOHEXIMIDE	NULL
PROTECTS	NULL
CFU-GM	NULL
FROM	NULL
Ara-C	NULL
mean	NULL
for	NULL
the	NULL
controls	NULL
are	NULL
:	NULL
normal	NULL
bone	NULL
marrow	NULL
,	NULL
88	NULL
+	NULL
14/10	NULL
``	NULL
cells	NULL
;	NULL
CML	NULL
peripheral	NULL
blood	NULL
424	NULL
+	NULL
217/2	NULL
x	NULL
10°	NULL
cells	NULL
;	NULL
HL-60	NULL
,	NULL
73	NULL
+	NULL
13/2	NULL
x	NULL
10°	NULL
cells	NULL
;	NULL
KG-1	NULL
,	NULL
32	NULL
+	NULL
14/2	NULL
x	NULL
10°	NULL
cells	NULL
.	NULL

Statistical	NULL
comparisons	NULL
were	NULL
performed	NULL
using	NULL
the	NULL
paired	NULL
Student	NULL
's	NULL
?	NULL

test	NULL
.	NULL

RESULTS	NULL
Normal	NULL
bone	NULL
marrow	NULL
.	NULL

-	NULL
Exposure	NULL
of	NULL
normal	NULL
bone	NULL
marrow	NULL
mononuclear	NULL
cells	NULL
to	NULL
cycloheximide	NULL
for	NULL
one	NULL
hour	NULL
before	NULL
treatment	NULL
with	NULL
Ara-C	NULL
significantly	NULL
increased	NULL
the	NULL
percentage	NULL
of	NULL
surviving	NULL
CFU-GM	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Exposure	NULL
to	NULL
1	NULL
ug/ml	NULL
of	NULL
Ara-C	NULL
for	NULL
three	NULL
hours	NULL
resulted	NULL
in	NULL
less	NULL
than	NULL
50	NULL
%	NULL
colony	NULL
survival	NULL
,	NULL
which	NULL
increased	NULL
if	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
cycloheximide	NULL
at	NULL
1	NULL
ug/ml	NULL
and	NULL
significantly	NULL
increased	NULL
with	NULL
10	NULL
ug/ml	NULL
(	NULL
P	NULL
<	NULL
.02	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
toxicity	NULL
from	NULL
a	NULL
higher-dose	NULL
Ara-C	NULL
exposure	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
could	NULL
be	NULL
ameliorated	NULL
by	NULL
one	NULL
hour	NULL
of	NULL
pretreatment	NULL
with	NULL
cycloheximide	NULL
at	NULL
1	NULL
ug/ml	NULL
(	NULL
P	NULL
<	NULL
.01	NULL
)	NULL
or	NULL
10	NULL
ug/ml	NULL
(	NULL
P	NULL
<	NULL
.001	NULL
)	NULL
.	NULL

Cycloheximide	NULL
itself	NULL
was	NULL
only	NULL
minimally	NULL
toxic	NULL
to	NULL
CFU-GM	NULL
at	NULL
this	NULL
duration	NULL
of	NULL
exposure	NULL
.	NULL

When	NULL
Ara-C	NULL
exposure	NULL
was	NULL
increased	NULL
from	NULL
three	NULL
hours	NULL
to	NULL
17	NULL
hours	NULL
,	NULL
significant	NULL
protection	NULL
was	NULL
still	NULL
afforded	NULL
if	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
cycloheximide	NULL
for	NULL
one	NULL
hour	NULL
before	NULL
addition	NULL
of	NULL
Ara-C	NULL
.	NULL

However	NULL
,	NULL
with	NULL
the	NULL
increased	NULL
exposure	NULL
time	NULL
,	NULL
cycloheximide	NULL
itself	NULL
was	NULL
toxic	NULL
at	NULL
the	NULL
higher	NULL
concentration	NULL
.	NULL

Ara-C	NULL
cytotoxicity	NULL
at	NULL
1	NULL
ug/mL	NULL
was	NULL
reduced	NULL
with	NULL
significantly	NULL
increased	NULL
colony	NULL
survival	NULL
when	NULL
cells	NULL
were	NULL
preexposed	NULL
to	NULL
cycloheximide	NULL
at	NULL
1	NULL
ug/mL	NULL
(	NULL
P	NULL
<	NULL
.005	NULL
)	NULL
.	NULL

Colony	NULL
survival	NULL
after	NULL
a	NULL
17-hour	NULL
,	NULL
10	NULL
ug/ml	NULL
Ara-C	NULL
incubation	NULL
could	NULL
be	NULL
increased	NULL
with	NULL
cycloheximide	NULL
at	NULL
both	NULL
1	NULL
ug/mL	NULL
(	NULL
P	NULL
<	NULL
.01	NULL
)	NULL
or	NULL
10	NULL
ug/ml	NULL
(	NULL
P	NULL
<	NULL
.05	NULL
)	NULL
.	NULL

In	NULL
three	NULL
experiments	NULL
,	NULL
increasing	NULL
cycloheximide	NULL
preexposure	NULL
from	NULL
one	NULL
hour	NULL
to	NULL
six	NULL
hours	NULL
resulted	NULL
in	NULL
no	NULL
additional	NULL
protective	NULL
effect	NULL
.	NULL

Simultaneous	NULL
addition	NULL
of	NULL
cycloheximide	NULL
and	NULL
Ara-C	NULL
failed	NULL
to	NULL
yield	NULL
any	NULL
protective	NULL
effect	NULL
.	NULL

In	NULL
cultures	NULL
with	NULL
1	NULL
or	NULL
10	NULL
ug/ml	NULL
Ara-C	NULL
and	NULL
no	NULL
cycloheximide	NULL
,	NULL
the	NULL
percentage	NULL
of	NULL
CFU-GM	NULL
survivals	NULL
were	NULL
45	NULL
%	NULL
+	NULL
7	NULL
%	NULL
and	NULL
12	NULL
%	NULL
+	NULL
6	NULL
%	NULL
,	NULL
respectively	NULL
.	NULL

In	NULL
three	NULL
experiments	NULL
,	NULL
the	NULL
simultaneous	NULL
addition	NULL
of	NULL
1	NULL
ug/mL	NULL
cycloheximide	NULL
to	NULL
the	NULL
Ara-C	NULL
Table	NULL
1	NULL
.	NULL

Effect	NULL
of	NULL
Preincubation	NULL
in	NULL
Cycloheximide	NULL
on	NULL
Survival	NULL
of	NULL
Normal	NULL
Bone	NULL
Marrow	NULL
CFU-GM	NULL
Exposed	NULL
to	NULL
Ara-C	NULL
Cycloheximide	NULL
AraC	NULL
{	NULL
ug/ml	NULL
)	NULL
(	NULL
ug/ml	NULL
)	NULL
0	NULL
1	NULL
10	NULL
0	NULL
100	NULL
90	NULL
+	NULL
3*	NULL
87	NULL
x	NULL
4	NULL
3-hour	NULL
Ara-C	NULL
1	NULL
47	NULL
x	NULL
4	NULL
58	NULL
+	NULL
5	NULL
68	NULL
x	NULL
5t	NULL
10	NULL
21	NULL
+	NULL
3	NULL
34	NULL
+	NULL
5¢	NULL
38	NULL
+	NULL
3§	NULL
0	NULL
100	NULL
93	NULL
£	NULL
5	NULL
58	NULL
+	NULL
8	NULL
17-hour	NULL
Ara-C	NULL
1	NULL
29	NULL
-	NULL
61	NULL
+4	NULL
]	NULL
44	NULL
+	NULL
6	NULL
10	NULL
4	NULL
£	NULL
1	NULL
13	NULL
+	NULL
3¢	NULL
10	NULL
+	NULL
21	NULL
*Mean	NULL
CFU-GM	NULL
survival	NULL
expressed	NULL
as	NULL
percentage	NULL
of	NULL
the	NULL
CFU-GM	NULL
observed	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Ara-C	NULL
or	NULL
cycloheximide	NULL
(	NULL
+	NULL
SE	NULL
of	NULL
the	NULL
mean	NULL
)	NULL
.	NULL

Six	NULL
normal	NULL
bone	NULL
marrow	NULL
samples	NULL
were	NULL
studied	NULL
for	NULL
three-hour	NULL
and	NULL
for	NULL
17-hour	NULL
Ara-C	NULL
exposure	NULL
times	NULL
.	NULL

{	NULL
CFU-GM	NULL
|	NULL
survival	NULL
with	NULL
cycloheximide	NULL
and	NULL
Ara-C	NULL
significantly	NULL
increased	NULL
compared	NULL
to	NULL
Ara-C	NULL
alone	NULL
(	NULL
P	NULL
<	NULL
.02	NULL
)	NULL
.	NULL

See	NULL
t	NULL
,	NULL
P	NULL
<	NULL
.01	NULL
.	NULL

§See	NULL
t	NULL
,	NULL
P	NULL
<	NULL
.001	NULL
.	NULL

See	NULL
t	NULL
,	NULL
P	NULL
<	NULL
.005	NULL
.	NULL

``	NULL
See	NULL
t	NULL
,	NULL
P	NULL
<	NULL
.05	NULL
.	NULL

831	NULL
Table	NULL
2	NULL
.	NULL

Effect	NULL
of	NULL
Preincubation	NULL
in	NULL
Cycloheximide	NULL
on	NULL
Survival	NULL
of	NULL
CFU-GM	NULL
from	NULL
CML	NULL
Peripheral	NULL
Blood	NULL
Exposed	NULL
to	NULL
Ara-C	NULL
for	NULL
Three	NULL
Hours	NULL
Cycloheximide	NULL
Ara-C	NULL
{	NULL
g/mL	NULL
}	NULL
{	NULL
ag/mL	NULL
)	NULL
0	NULL
1	NULL
10	NULL
0	NULL
100	NULL
76	NULL
+	NULL
5*	NULL
63	NULL
+	NULL
6	NULL
1	NULL
26	NULL
+	NULL
5	NULL
20	NULL
+	NULL
4t	NULL
15	NULL
+	NULL
5¢	NULL
10	NULL
12	NULL
+	NULL
3	NULL
9	NULL
+	NULL
3	NULL
8	NULL
+	NULL
3t	NULL
Samples	NULL
from	NULL
seven	NULL
of	NULL
the	NULL
nine	NULL
patients	NULL
studied	NULL
had	NULL
been	NULL
cryopre-served	NULL
.	NULL

*Mean	NULL
CFU-GM	NULL
survival	NULL
expressed	NULL
as	NULL
percentage	NULL
of	NULL
the	NULL
CFU-GM	NULL
observed	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Ara-C	NULL
or	NULL
cycloheximide	NULL
(	NULL
+	NULL
SE	NULL
of	NULL
the	NULL
mean	NULL
)	NULL
.	NULL

{	NULL
CFU-GM	NULL
survival	NULL
with	NULL
cycloheximide	NULL
and	NULL
Ara-C	NULL
significantly	NULL
decreased	NULL
compared	NULL
with	NULL
Ara-C	NULL
alone	NULL
(	NULL
P	NULL
<	NULL
.02	NULL
)	NULL
.	NULL

{	NULL
See	NULL
t	NULL
,	NULL
P	NULL
<	NULL
.001.	NULL
containing	NULL
cell	NULL
suspensions	NULL
resulted	NULL
in	NULL
CFU-GM	NULL
survival	NULL
for	NULL
1	NULL
and	NULL
10	NULL
ug/ml	NULL
AraC	NULL
of	NULL
35	NULL
%	NULL
+	NULL
5	NULL
%	NULL
and	NULL
9	NULL
%	NULL
+	NULL
6	NULL
%	NULL
.	NULL

Using	NULL
10	NULL
ug/mL	NULL
cycloheximide	NULL
,	NULL
the	NULL
mean	NULL
CFU-GM	NULL
survivals	NULL
were	NULL
32	NULL
%	NULL
+	NULL
6	NULL
%	NULL
(	NULL
P	NULL
<	NULL
.05	NULL
)	NULL
and	NULL
6	NULL
%	NULL
+	NULL
4	NULL
%	NULL
,	NULL
respectively	NULL
.	NULL

Chronic	NULL
myelogenous	NULL
leukemia	NULL
.	NULL

Cycloheximide	NULL
pretreatment	NULL
of	NULL
mononuclear	NULL
cells	NULL
from	NULL
nine	NULL
patients	NULL
with	NULL
CML	NULL
failed	NULL
to	NULL
protect	NULL
CFU-GM	NULL
from	NULL
Ara-C-induced	NULL
cytotoxicity	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

A	NULL
three-hour	NULL
Ara-C	NULL
exposure	NULL
at	NULL
1	NULL
ug/mL	NULL
yielded	NULL
26	NULL
%	NULL
+	NULL
50	NULL
%	NULL
colony	NULL
survival	NULL
,	NULL
which	NULL
was	NULL
not	NULL
increased	NULL
,	NULL
but	NULL
was	NULL
,	NULL
on	NULL
the	NULL
contrary	NULL
,	NULL
significantly	NULL
decreased	NULL
when	NULL
cells	NULL
were	NULL
pretreated	NULL
for	NULL
one	NULL
hour	NULL
with	NULL
cycloheximide	NULL
at	NULL
1	NULL
or	NULL
10	NULL
ug/ml	NULL
.	NULL

With	NULL
a	NULL
higher	NULL
Ara-C	NULL
dose	NULL
(	NULL
10	NULL
ug/mL	NULL
)	NULL
,	NULL
preexposure	NULL
to	NULL
cycloheximide	NULL
was	NULL
minimally	NULL
toxic	NULL
at	NULL
1	NULL
ug/mL	NULL
but	NULL
was	NULL
toxic	NULL
at	NULL
10	NULL
ug/ml	NULL
.	NULL

Acute	NULL
leukemia	NULL
cell	NULL
lines	NULL
HL-60	NULL
and	NULL
KG-1	NULL
.	NULL

-	NULL
Pretreatment	NULL
of	NULL
HL-60	NULL
cells	NULL
for	NULL
one	NULL
hour	NULL
with	NULL
cycloheximide	NULL
failed	NULL
to	NULL
protect	NULL
clonogenic	NULL
cells	NULL
from	NULL
toxicity	NULL
induced	NULL
by	NULL
a	NULL
three-hour	NULL
exposure	NULL
to	NULL
Ara-C	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

In	NULL
five	NULL
experiments	NULL
,	NULL
cycloheximide	NULL
alone	NULL
at	NULL
1	NULL
ug/mL	NULL
was	NULL
nontoxic	NULL
(	NULL
mean	NULL
CFU-GM	NULL
survival	NULL
91	NULL
%	NULL
+	NULL
11	NULL
%	NULL
)	NULL
.	NULL

As	NULL
in	NULL
the	NULL
experiments	NULL
using	NULL
CML	NULL
cells	NULL
,	NULL
cycloheximide	NULL
decreased	NULL
colony	NULL
survival	NULL
at	NULL
both	NULL
1	NULL
and	NULL
10	NULL
ug/mL	NULL
Ara-C.	NULL
Increasing	NULL
exposure	NULL
to	NULL
Ara-C	NULL
to	NULL
17	NULL
hours	NULL
decreased	NULL
the	NULL
percentage	NULL
of	NULL
CFU-GM	NULL
survival	NULL
.	NULL

Again	NULL
,	NULL
however	NULL
,	NULL
no	NULL
protec-	NULL
Table	NULL
3	NULL
.	NULL

Effect	NULL
of	NULL
Preincubation	NULL
in	NULL
Cycloheximide	NULL
on	NULL
Survival	NULL
of	NULL
HL-60	NULL
CFU-GM	NULL
Exposed	NULL
to	NULL
Ara-C	NULL
Cycloheximide	NULL
Ara-C	NULL
{	NULL
ug/ml	NULL
)	NULL
{	NULL
g/mL	NULL
)	NULL
0	NULL
1	NULL
10	NULL
3-hour	NULL
Ara-C	NULL
0	NULL
100	NULL
91	NULL
%	NULL
11*	NULL
_	NULL
82	NULL
*	NULL
9	NULL
1	NULL
62	NULL
+	NULL
4	NULL
48	NULL
+	NULL
4¢	NULL
51	NULL
+	NULL
5	NULL
10	NULL
57	NULL
+	NULL
11	NULL
46	NULL
+	NULL
9	NULL
43	NULL
+	NULL
9¢	NULL
17-hour	NULL
Ara-C	NULL
0	NULL
100	NULL
74	NULL
+	NULL
4	NULL
49	NULL
+	NULL
11	NULL
1	NULL
47	NULL
x	NULL
3	NULL
36	NULL
+	NULL
3	NULL
22	NULL
+	NULL
3¢	NULL
10	NULL
29	NULL
+	NULL
2	NULL
24	NULL
+	NULL
0	NULL
19	NULL
+	NULL
1§	NULL
*Mean	NULL
CFU-GM	NULL
survival	NULL
for	NULL
five	NULL
experiments	NULL
expressed	NULL
as	NULL
percentage	NULL
of	NULL
the	NULL
CFU-GM	NULL
observed	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Ara-C	NULL
or	NULL
cycloheximide	NULL
(	NULL
+	NULL
SE	NULL
of	NULL
the	NULL
mean	NULL
}	NULL
.	NULL

{	NULL
CFU-GM	NULL
|	NULL
survival	NULL
with	NULL
cycloheximide	NULL
and	NULL
Ara-C	NULL
significantly	NULL
decreased	NULL
compared	NULL
with	NULL
Ara-C	NULL
alone	NULL
(	NULL
P	NULL
<	NULL
.05	NULL
)	NULL
.	NULL

{	NULL
See	NULL
t	NULL
,	NULL
P	NULL
<	NULL
.002	NULL
.	NULL

§See	NULL
t	NULL
,	NULL
P	NULL
<	NULL
.02	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

832	NULL
tive	NULL
effect	NULL
of	NULL
cycloheximide	NULL
was	NULL
observed	NULL
,	NULL
and	NULL
cycloheximide	NULL
cytotoxicity	NULL
appeared	NULL
additive	NULL
with	NULL
Ara-C.	NULL
A	NULL
comparison	NULL
of	NULL
CFU-GM	NULL
survival	NULL
results	NULL
with	NULL
three-hour	NULL
Ara-C	NULL
incubation	NULL
for	NULL
normal	NULL
bone	NULL
marrow	NULL
,	NULL
CML	NULL
blood	NULL
,	NULL
and	NULL
HL-60	NULL
cells	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
1	NULL
.	NULL

In	NULL
two	NULL
experiments	NULL
with	NULL
KG-1	NULL
cells	NULL
using	NULL
a	NULL
three-hour	NULL
Ara-C	NULL
exposure	NULL
,	NULL
cycloheximide	NULL
at	NULL
1	NULL
ug/mL	NULL
(	NULL
nontoxic	NULL
,	NULL
CFU-C	NULL
survival	NULL
105	NULL
%	NULL
)	NULL
did	NULL
not	NULL
protect	NULL
CFU-GM	NULL
.	NULL

Survival	NULL
of	NULL
CFU-GM	NULL
was	NULL
20	NULL
%	NULL
with	NULL
1	NULL
ug/mL	NULL
Ara-C	NULL
alone	NULL
and	NULL
17	NULL
%	NULL
with	NULL
preexposure	NULL
to	NULL
cycloheximide	NULL
;	NULL
17	NULL
%	NULL
with	NULL
10	NULL
ug/ml	NULL
Ara-C	NULL
alone	NULL
and	NULL
13	NULL
%	NULL
with	NULL
cycloheximide	NULL
posure	NULL
.	NULL

DISCUSSION	NULL
The	NULL
data	NULL
presented	NULL
here	NULL
demonstrate	NULL
that	NULL
cycloheximide	NULL
pretreatment	NULL
reduces	NULL
Ara-C	NULL
toxicity	NULL
on	NULL
normal	NULL
human	NULL
bone	NULL
marrow	NULL
CFU-GM	NULL
,	NULL
in	NULL
some	NULL
instances	NULL
by	NULL
twofold	NULL
to	NULL
threefold	NULL
.	NULL

Similar	NULL
cycloheximide	NULL
treatment	NULL
of	NULL
CML	NULL
or	NULL
acute	NULL
nonlymphocytic	NULL
leukemia	NULL
cell	NULL
lines	NULL
failed	NULL
to	NULL
increase	NULL
colony	NULL
survival	NULL
and	NULL
in	NULL
fact	NULL
enhanced	NULL
the	NULL
toxicity	NULL
of	NULL
Ara-C	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
cycloheximide	NULL
might	NULL
improve	NULL
the	NULL
therapeutic	NULL
index	NULL
of	NULL
Ara-C	NULL
.	NULL

While	NULL
previous	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
protein	NULL
synthesis	NULL
inhibitors	NULL
protect	NULL
rat	NULL
intestinal	NULL
crypt	NULL
cells	NULL
,	NULL
``	NULL
rat	NULL
bone	NULL
marrow	NULL
,	NULL
*	NULL
``	NULL
and	NULL
chinese	NULL
hamster	NULL
ovary	NULL
cells®	NULL
from	NULL
cytotoxic	NULL
agents	NULL
,	NULL
this	NULL
study	NULL
is	NULL
,	NULL
to	NULL
our	NULL
knowledge	NULL
,	NULL
the	NULL
first	NULL
to	NULL
demonstrate	NULL
such	NULL
an	NULL
effect	NULL
on	NULL
human	NULL
hematopoietic	NULL
cells*	NULL
'	NULL
and	NULL
the	NULL
first	NULL
to	NULL
show	NULL
cycloheximide	NULL
's	NULL
differential	NULL
protection	NULL
of	NULL
normal	NULL
v	NULL
malignant	NULL
cells	NULL
from	NULL
a	NULL
cytotoxic	NULL
agent	NULL
in	NULL
a	NULL
human	NULL
cell	NULL
culture	NULL
system	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
cycloheximide	NULL
in	NULL
affecting	NULL
Ara-C	NULL
cytotoxicity	NULL
has	NULL
not	NULL
been	NULL
specifically	NULL
evaluated	NULL
in	NULL
our	NULL
study	NULL
but	NULL
could	NULL
be	NULL
ascribed	NULL
to	NULL
its	NULL
cell	NULL
cycle	NULL
effect	NULL
.	NULL

In	NULL
normal	NULL
100	NULL
p	NULL
A	NULL
Ara-C	NULL
|jug/ml	NULL
sof	NULL
p	NULL
<	NULL
.	NULL

02	NULL
Normals	NULL
CML	NULL
HL-60	NULL
100r	NULL
B8	NULL
.	NULL

Ara-C	NULL
1Opug/m	NULL
!	NULL

%	NULL
SURVIVING	NULL
CFU-GM	NULL
Nor	NULL
mais	NULL
CML	NULL
HL-60	NULL
Fig	NULL
1	NULL
.	NULL

-	NULL
Effect	NULL
of	NULL
cycloheximide	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
on	NULL
CFU-GM	NULL
toxicity	NULL
of	NULL
Ara-C	NULL
using	NULL
normal	NULL
bone	NULL
marrow	NULL
,	NULL
blood	NULL
from	NULL
patients	NULL
with	NULL
chronic	NULL
myeloid	NULL
leukemia	NULL
,	NULL
and	NULL
the	NULL
clonogenic	NULL
acute	NULL
nonlymphocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
,	NULL
HL-60	NULL
.	NULL

The	NULL
height	NULL
of	NULL
the	NULL
bars	NULL
represents	NULL
the	NULL
mean	NULL
(	NULL
+	NULL
SE	NULL
)	NULL
CFU-GM	NULL
survival	NULL
expressed	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
the	NULL
CFU-GM	NULL
observed	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Ara-C	NULL
or	NULL
cycloheximide	NULL
.	NULL

{	NULL
A	NULL
)	NULL
Ara-C	NULL
1	NULL
ug/mL	NULL
;	NULL
(	NULL
B	NULL
)	NULL
Ara-C	NULL
10	NULL
ug/ml	NULL
.	NULL

C	NULL
,	NULL
Cultures	NULL
without	NULL
cycloheximide	NULL
.	NULL

BBI	NULL
,	NULL
Samples	NULL
exposed	NULL
to	NULL
cycloheximide	NULL
prior	NULL
to	NULL
Ara-C	NULL
incubation	NULL
.	NULL

SLAPAK	NULL
,	NULL
FINE	NULL
,	NULL
AND	NULL
RICHMAN	NULL
cells	NULL
,	NULL
initiation	NULL
of	NULL
DNA	NULL
synthesis	NULL
is	NULL
preceded	NULL
by	NULL
synthesis	NULL
of	NULL
a	NULL
labile	NULL
protein	NULL
.	NULL
``	NULL

Treatment	NULL
with	NULL
cycloheximide	NULL
arrests	NULL
normal	NULL
cells	NULL
in	NULL
G1	NULL
,	NULL
probably	NULL
by	NULL
preventing	NULL
the	NULL
synthesis	NULL
of	NULL
this	NULL
labile	NULL
protein	NULL
.	NULL
``	NULL

Data	NULL
suggest	NULL
that	NULL
transformed	NULL
cells	NULL
lack	NULL
this	NULL
stringent	NULL
control	NULL
and	NULL
may	NULL
not	NULL
be	NULL
as	NULL
susceptible	NULL
to	NULL
cycle	NULL
arrest	NULL
,	NULL
``	NULL
``	NULL
``	NULL
'	NULL
perhaps	NULL
because	NULL
the	NULL
la	NULL
bile	NULL
protein	NULL
is	NULL
not	NULL
necessary	NULL
,	NULL
acquires	NULL
increased	NULL
stability	NULL
,	NULL
or	NULL
is	NULL
synthesized	NULL
at	NULL
an	NULL
increased	NULL
rate	NULL
.	NULL
``	NULL

''	NULL
Baseline	NULL
differences	NULL
between	NULL
normal	NULL
and	NULL
malignant	NULL
myeloid	NULL
progenitors	NULL
in	NULL
the	NULL
kinetics	NULL
of	NULL
cell	NULL
proliferation	NULL
or	NULL
in	NULL
drug	NULL
metabolism	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
differential	NULL
protection	NULL
of	NULL
normal	NULL
cells	NULL
observed	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
pretreatment	NULL
of	NULL
normal	NULL
cells	NULL
with	NULL
cycloheximide	NULL
arrests	NULL
the	NULL
cells	NULL
in	NULL
G1	NULL
,	NULL
protecting	NULL
them	NULL
from	NULL
S-phase	NULL
specific	NULL
agents	NULL
,	NULL
while	NULL
malignant	NULL
cells	NULL
may	NULL
not	NULL
be	NULL
arrested	NULL
and	NULL
proceed	NULL
from	NULL
G1	NULL
to	NULL
S	NULL
with	NULL
subsequent	NULL
susceptibility	NULL
to	NULL
Ara-C-induced	NULL
destruction	NULL
.	NULL

L-Asparaginase	NULL
,	NULL
a	NULL
protein	NULL
synthesis-inhibiting	NULL
enzyme	NULL
that	NULL
is	NULL
useful	NULL
in	NULL
treating	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
,	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
exhibit	NULL
schedule-dependent	NULL
synergy	NULL
with	NULL
Ara-C	NULL
on	NULL
L5178Y	NULL
murine	NULL
leukemia	NULL
when	NULL
Ara-C	NULL
treatment	NULL
is	NULL
followed	NULL
by	NULL
asparaginase	NULL
.	NULL

Pretreatment	NULL
of	NULL
cells	NULL
with	NULL
asparaginase	NULL
antagonizes	NULL
the	NULL
antileukemic	NULL
effect	NULL
of	NULL
Ara-C.	NULL
``	NULL
Our	NULL
results	NULL
,	NULL
with	NULL
a	NULL
different	NULL
protein	NULL
synthesis	NULL
inhibitor	NULL
,	NULL
using	NULL
an	NULL
in	NULL
vitro	NULL
human	NULL
system	NULL
failed	NULL
to	NULL
show	NULL
this	NULL
type	NULL
of	NULL
antago-nism	NULL
.	NULL

Whether	NULL
Ara-C	NULL
treatment	NULL
followed	NULL
by	NULL
cycloheximide	NULL
exhibits	NULL
schedule-dependent	NULL
synergy	NULL
in	NULL
our	NULL
system	NULL
is	NULL
unknown	NULL
,	NULL
although	NULL
our	NULL
results	NULL
indicate	NULL
that	NULL
simultaneous	NULL
addition	NULL
of	NULL
Ara-C	NULL
and	NULL
cycloheximide	NULL
is	NULL
no	NULL
different	NULL
than	NULL
Ara-C	NULL
alone	NULL
.	NULL

In	NULL
animal	NULL
systems	NULL
,	NULL
cycloheximide	NULL
protection	NULL
of	NULL
normal	NULL
cells	NULL
has	NULL
also	NULL
been	NULL
described	NULL
with	NULL
other	NULL
S-phase	NULL
specific	NULL
agents	NULL
,	NULL
``	NULL
as	NULL
well	NULL
as	NULL
drugs	NULL
that	NULL
do	NULL
not	NULL
work	NULL
exclusively	NULL
in	NULL
the	NULL
S-phase	NULL
,	NULL
``	NULL
suggesting	NULL
that	NULL
cycloheximide	NULL
may	NULL
be	NULL
useful	NULL
in	NULL
combination	NULL
with	NULL
several	NULL
active	NULL
antineoplastic	NULL
drugs	NULL
as	NULL
well	NULL
as	NULL
with	NULL
irradiation	NULL
.	NULL
``	NULL

If	NULL
cycloheximide	NULL
preferentially	NULL
protected	NULL
normal	NULL
hematopoietic	NULL
cells	NULL
from	NULL
alkylating	NULL
agents	NULL
,	NULL
such	NULL
as	NULL
cyclophosphamide	NULL
,	NULL
it	NULL
might	NULL
prove	NULL
useful	NULL
in	NULL
preparing	NULL
remission	NULL
bone	NULL
marrow	NULL
for	NULL
autologous	NULL
transfusion	NULL
in	NULL
acute	NULL
leukemia	NULL
.	NULL

At	NULL
present	NULL
,	NULL
the	NULL
options	NULL
for	NULL
``	NULL
purging	NULL
``	NULL
residual	NULL
malignant	NULL
cells	NULL
from	NULL
harvested	NULL
autologous	NULL
marrow	NULL
in	NULL
vitro	NULL
include	NULL
monoclonal	NULL
antibody	NULL
treatment	NULL
and	NULL
exposure	NULL
to	NULL
cytotoxic	NULL
drugs	NULL
,	NULL
such	NULL
as	NULL
the	NULL
cyclophosphamide	NULL
analog	NULL
4-hydroperoxycyclophosphamide	NULL
(	NULL
4-HC	NULL
)	NULL
,	NULL
which	NULL
has	NULL
been	NULL
shown	NULL
(	NULL
in	NULL
an	NULL
animal	NULL
leukemia	NULL
model	NULL
)	NULL
to	NULL
have	NULL
some	NULL
specificity	NULL
for	NULL
malignant	NULL
progenitors	NULL
.	NULL
``	NULL

Cycloheximide	NULL
might	NULL
improve	NULL
the	NULL
selective	NULL
removal	NULL
of	NULL
malignant	NULL
cells	NULL
with	NULL
4-HC	NULL
,	NULL
Ara-C	NULL
,	NULL
or	NULL
other	NULL
agents	NULL
.	NULL

The	NULL
results	NULL
of	NULL
this	NULL
study	NULL
may	NULL
have	NULL
direct	NULL
clinical	NULL
applica-tion	NULL
,	NULL
since	NULL
both	NULL
cycloheximide	NULL
and	NULL
Ara-C	NULL
have	NULL
been	NULL
used	NULL
clinically	NULL
in	NULL
doses	NULL
expected	NULL
or	NULL
documented	NULL
to	NULL
produce	NULL
plasma	NULL
levels	NULL
approximating	NULL
the	NULL
1	NULL
and	NULL
10	NULL
ug/mL	NULL
used	NULL
in	NULL
vitro	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
,	NULL
intravenous	NULL
cycloheximide	NULL
had	NULL
limited	NULL
toxicity	NULL
when	NULL
evaluated	NULL
as	NULL
an	NULL
antipyretic	NULL
agent	NULL
in	NULL
Hodgkin	NULL
's	NULL
dis-ease	NULL
.	NULL
``	NULL

Our	NULL
data	NULL
show	NULL
that	NULL
short-term	NULL
exposure	NULL
to	NULL
cycloheximide	NULL
is	NULL
minimally	NULL
toxic	NULL
to	NULL
normal	NULL
CFU-GM	NULL
and	NULL
protects	NULL
these	NULL
normal	NULL
progenitors	NULL
from	NULL
the	NULL
cytotoxicity	NULL
of	NULL
Ara-C	NULL
,	NULL
one	NULL
of	NULL
the	NULL
most	NULL
active	NULL
drugs	NULL
used	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
myeloid	NULL
leukemias	NULL
.	NULL

Whether	NULL
cycloheximide	NULL
can	NULL
also	NULL
protect	NULL
the	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

CYCLOHEXIMIDE	NULL
PROTECTS	NULL
CFU-GM	NULL
FROM	NULL
Ara-C	NULL
pluripotential	NULL
stem	NULL
cell	NULL
can	NULL
not	NULL
be	NULL
fully	NULL
determined	NULL
with	NULL
current	NULL
techniques	NULL
.	NULL

However	NULL
,	NULL
in	NULL
autologous	NULL
bone	NULL
marrow	NULL
transplantation	NULL
,	NULL
a	NULL
direct	NULL
correlation	NULL
has	NULL
been	NULL
documented	NULL
between	NULL
total	NULL
CFU-GM	NULL
infused	NULL
and	NULL
rapidity	NULL
of	NULL
granulocyte	NULL
recovery	NULL
,	NULL
suggesting	NULL
that	NULL
protection	NULL
of	NULL
CFU-GM	NULL
could	NULL
at	NULL
least	NULL
enhance	NULL
granulocyte	NULL
recovery	NULL
.	NULL
``	NULL

Successful	NULL
treatment	NULL
of	NULL
leukemia	NULL
in	NULL
vivo	NULL
requires	NULL
complete	NULL
erradication	NULL
of	NULL
malignant	NULL
clones	NULL
with	NULL
survival	NULL
of	NULL
sufficient	NULL
normal	NULL
stem	NULL
cells	NULL
to	NULL
repopulate	NULL
the	NULL
hematopoietic	NULL
system	NULL
.	NULL

The	NULL
present	NULL
study	NULL
suggests	NULL
that	NULL
combination	NULL
therapy	NULL
with	NULL
cycloheximide	NULL
and	NULL
833	NULL
Ara-C	NULL
might	NULL
preferentially	NULL
destroy	NULL
the	NULL
abnormal	NULL
clones	NULL
and	NULL
decrease	NULL
the	NULL
degree	NULL
of	NULL
myelosuppression	NULL
associated	NULL
with	NULL
intensive	NULL
antileukemia	NULL
therapy	NULL
.	NULL

ACKNOWLEDGMENT	NULL
We	NULL
are	NULL
indebted	NULL
to	NULL
H.	NULL
Koeffler	NULL
(	NULL
UCLA	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Los	NULL
Angeles	NULL
)	NULL
for	NULL
providing	NULL
the	NULL
KG-1	NULL
cell	NULL
line	NULL
and	NULL
to	NULL
E.	NULL
Lester	NULL
(	NULL
Univer-sity	NULL
of	NULL
Chicago	NULL
)	NULL
for	NULL
providing	NULL
the	NULL
HL-60	NULL
ceils	NULL
obtained	NULL
through	NULL
the	NULL
courtesy	NULL
of	NULL
R.	NULL
Gallo	NULL
of	NULL
the	NULL
National	NULL
Cancer	NULL
Institute	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Barlogie	NULL
B	NULL
,	NULL
Drewinko	NULL
B	NULL
,	NULL
Dosik	NULL
G	NULL
,	NULL
Freireich	NULL
EJ	NULL
:	NULL
Cell	NULL
kinetics	NULL
and	NULL
the	NULL
management	NULL
of	NULL
malignant	NULL
disease	NULL
.	NULL

Acta	NULL
Pathol	NULL
Microbiol	NULL
Immunol	NULL
Scand	NULL
274:385	NULL
,	NULL
1981	NULL
(	NULL
suppl	NULL
)	NULL
2	NULL
.	NULL

Tannock	NULL
I	NULL
:	NULL
Cell	NULL
kinetics	NULL
and	NULL
chemotherapy	NULL
:	NULL
A	NULL
critical	NULL
review	NULL
.	NULL

Cancer	NULL
Treat	NULL
Rep	NULL
62:1117	NULL
,	NULL
1978	NULL
3	NULL
.	NULL

Lieberman	NULL
MW	NULL
,	NULL
Verbin	NULL
RS	NULL
,	NULL
Landay	NULL
M	NULL
,	NULL
Liang	NULL
H	NULL
,	NULL
Farber	NULL
E	NULL
,	NULL
Lee	NULL
T	NULL
,	NULL
Starr	NULL
R	NULL
:	NULL
A	NULL
probable	NULL
role	NULL
for	NULL
protein	NULL
synthesis	NULL
in	NULL
intestinal	NULL
epithelial	NULL
cell	NULL
damage	NULL
induced	NULL
in	NULL
vivo	NULL
by	NULL
cytosine	NULL
arabinoside	NULL
,	NULL
nitrogen	NULL
mustard	NULL
,	NULL
or	NULL
x-irradiation	NULL
.	NULL

Cancer	NULL
Res	NULL
30:942	NULL
,	NULL
1970	NULL
4	NULL
.	NULL

Ben-Ishay	NULL
Z	NULL
,	NULL
Farber	NULL
E	NULL
:	NULL
Protective	NULL
effects	NULL
of	NULL
an	NULL
inhibitor	NULL
of	NULL
protein	NULL
synthesis	NULL
,	NULL
cycloheximide	NULL
,	NULL
on	NULL
bone	NULL
marrow	NULL
damage	NULL
induced	NULL
by	NULL
cytosine	NULL
arabinoside	NULL
or	NULL
nitrogen	NULL
mustard	NULL
.	NULL

Lab	NULL
Invest	NULL
33:478	NULL
,	NULL
1975	NULL
5	NULL
.	NULL

Weissberg	NULL
JB	NULL
,	NULL
Herion	NULL
JC	NULL
,	NULL
Walker	NULL
R1	NULL
,	NULL
Palmer	NULL
JG	NULL
:	NULL
Effect	NULL
of	NULL
cycloheximide	NULL
on	NULL
the	NULL
bone	NULL
marrow	NULL
toxicity	NULL
of	NULL
nitrogen	NULL
mustard	NULL
.	NULL

Cancer	NULL
Res	NULL
38:1	NULL
523	NULL
,	NULL
1978	NULL
6	NULL
.	NULL

Teodori	NULL
L	NULL
,	NULL
Barlogie	NULL
B	NULL
,	NULL
Drewinko	NULL
B	NULL
,	NULL
Swartzendruber	NULL
D	NULL
,	NULL
Mauro	NULL
F	NULL
:	NULL
Reduction	NULL
of	NULL
1	NULL
,	NULL
-D-Arabinofuranosylcytosine	NULL
and	NULL
Adriamycin	NULL
cytotoxicity	NULL
following	NULL
cell	NULL
cycle	NULL
arrest	NULL
by	NULL
anguidine	NULL
.	NULL

Cancer	NULL
Res	NULL
41:1263	NULL
,	NULL
1981	NULL
7	NULL
.	NULL

Schneiderman	NULL
MH	NULL
,	NULL
Dewey	NULL
WC	NULL
,	NULL
Highfield	NULL
DP	NULL
:	NULL
Inhibition	NULL
of	NULL
DNA	NULL
synthesis	NULL
in	NULL
synchronized	NULL
chinese	NULL
hamster	NULL
cells	NULL
treated	NULL
in	NULL
G1	NULL
with	NULL
cycloheximide	NULL
.	NULL

Exp	NULL
Cell	NULL
Res	NULL
67:147	NULL
,	NULL
1971	NULL
8	NULL
.	NULL

Brooks	NULL
RF	NULL
:	NULL
Continuous	NULL
protein	NULL
synthesis	NULL
is	NULL
required	NULL
to	NULL
maintain	NULL
the	NULL
probability	NULL
of	NULL
entry	NULL
into	NULL
S	NULL
phase	NULL
.	NULL

Cell	NULL
12:311	NULL
,	NULL
1977	NULL
9	NULL
.	NULL

Campisi	NULL
J	NULL
,	NULL
Medrano	NULL
EE	NULL
,	NULL
Morreo	NULL
G	NULL
,	NULL
Pardee	NULL
AB	NULL
:	NULL
Restriction	NULL
point	NULL
control	NULL
of	NULL
cell	NULL
growth	NULL
by	NULL
a	NULL
labile	NULL
protein	NULL
:	NULL
Evidence	NULL
of	NULL
increased	NULL
stability	NULL
in	NULL
transformed	NULL
cells	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
79:436	NULL
,	NULL
1982	NULL
10	NULL
.	NULL

Pardee	NULL
AB	NULL
,	NULL
James	NULL
LJ	NULL
:	NULL
Selective	NULL
killing	NULL
of	NULL
transformed	NULL
baby	NULL
hamster	NULL
kidney	NULL
(	NULL
BHK	NULL
)	NULL
cells	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
72:4994	NULL
,	NULL
1975	NULL
11	NULL
.	NULL

Medrano	NULL
EE	NULL
,	NULL
Pardee	NULL
AB	NULL
:	NULL
Prevalent	NULL
deficiency	NULL
in	NULL
tumor	NULL
cells	NULL
of	NULL
cycloheximide-induced	NULL
cycle	NULL
arrest	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
77:4123	NULL
,	NULL
1980	NULL
12	NULL
.	NULL

Collins	NULL
SJ	NULL
,	NULL
Gallo	NULL
RC	NULL
,	NULL
Gallagher	NULL
RE	NULL
:	NULL
Continuous	NULL
growth	NULL
and	NULL
differentiation	NULL
of	NULL
human	NULL
myeloid	NULL
leukemic	NULL
cells	NULL
in	NULL
suspension	NULL
cul-ture	NULL
.	NULL

Nature	NULL
270:347	NULL
,	NULL
1977	NULL
13	NULL
.	NULL

Koeffler	NULL
HP	NULL
,	NULL
Golde	NULL
DW	NULL
:	NULL
Acute	NULL
myelogenous	NULL
leukemia	NULL
:	NULL
A	NULL
human	NULL
cell	NULL
line	NULL
responsive	NULL
to	NULL
colony-stimulating	NULL
activity	NULL
.	NULL

Science	NULL
200:1153	NULL
,	NULL
1978	NULL
14	NULL
.	NULL

Koeffier	NULL
HP	NULL
,	NULL
Golde	NULL
DW	NULL
:	NULL
Human	NULL
myeloid	NULL
leukemia	NULL
cell	NULL
lines	NULL
:	NULL
A	NULL
review	NULL
.	NULL

Blood	NULL
56:344	NULL
,	NULL
1980	NULL
15	NULL
.	NULL

Boyum	NULL
A	NULL
:	NULL
Separation	NULL
of	NULL
leukocytes	NULL
from	NULL
blood	NULL
and	NULL
bone	NULL
marrow	NULL
.	NULL

Scand	NULL
J	NULL
Clin	NULL
Lab	NULL
Invest	NULL
21:1	NULL
,	NULL
1968	NULL
(	NULL
suppl	NULL
)	NULL
16	NULL
.	NULL

Richman	NULL
CM	NULL
,	NULL
Weiner	NULL
RS	NULL
,	NULL
Yankee	NULL
RA	NULL
:	NULL
Increase	NULL
in	NULL
circulating	NULL
stem	NULL
cells	NULL
following	NULL
chemotherapy	NULL
in	NULL
man	NULL
.	NULL

Blood	NULL
47:1031	NULL
,	NULL
1976	NULL
17	NULL
.	NULL

Weiner	NULL
RS	NULL
,	NULL
Richman	NULL
CM	NULL
,	NULL
Yankee	NULL
RA	NULL
:	NULL
Semicontinuous	NULL
flow	NULL
centrifugation	NULL
for	NULL
the	NULL
pheresis	NULL
of	NULL
immuno-competent	NULL
cells	NULL
and	NULL
stem	NULL
cells	NULL
.	NULL

Blood	NULL
49:391	NULL
,	NULL
1977	NULL
18	NULL
.	NULL

Parker	NULL
LM	NULL
,	NULL
Binder	NULL
N	NULL
,	NULL
Gelman	NULL
R	NULL
,	NULL
Richman	NULL
CM	NULL
,	NULL
Weiner	NULL
RS	NULL
,	NULL
Yankee	NULL
RA	NULL
:	NULL
Prolonged	NULL
cryopreservation	NULL
of	NULL
human	NULL
bone	NULL
marrow	NULL
.	NULL

Transplantation	NULL
31:454	NULL
,	NULL
1981	NULL
19	NULL
.	NULL

Iscove	NULL
NN	NULL
,	NULL
Senn	NULL
JS	NULL
,	NULL
Till	NULL
JE	NULL
,	NULL
McCulloch	NULL
EA	NULL
:	NULL
Colony	NULL
formation	NULL
by	NULL
normal	NULL
and	NULL
leukemic	NULL
human	NULL
bone	NULL
marrow	NULL
cells	NULL
in	NULL
culture	NULL
:	NULL
Effect	NULL
of	NULL
conditioned	NULL
medium	NULL
from	NULL
human	NULL
leukocytes	NULL
.	NULL

Blood	NULL
37:1	NULL
,	NULL
1971	NULL
20	NULL
.	NULL

Lau	NULL
L	NULL
,	NULL
McCulloch	NULL
EA	NULL
,	NULL
Till	NULL
JE	NULL
,	NULL
Price	NULL
GB	NULL
:	NULL
The	NULL
production	NULL
of	NULL
hematopoietic	NULL
growth	NULL
factors	NULL
by	NULL
PHA-stimulated	NULL
leukocytes	NULL
.	NULL

Exp	NULL
Hematol	NULL
6:1	NULL
14	NULL
,	NULL
1978	NULL
21	NULL
.	NULL

Slapak	NULL
CA	NULL
,	NULL
Fine	NULL
RL	NULL
,	NULL
Richman	NULL
CM	NULL
:	NULL
Protection	NULL
from	NULL
cytosine	NULL
arabinoside	NULL
induced	NULL
cytoxicity	NULL
on	NULL
human	NULL
bone	NULL
marrow	NULL
granulocyte/	NULL
macrophage	NULL
progenitors	NULL
(	NULL
CFU-GM	NULL
)	NULL
by	NULL
cycloheximide	NULL
.	NULL

Blood	NULL
62:163a	NULL
,	NULL
1983	NULL
22	NULL
.	NULL

Pardee	NULL
AB	NULL
:	NULL
A	NULL
restriction	NULL
point	NULL
for	NULL
control	NULL
of	NULL
normal	NULL
animal	NULL
cell	NULL
proliferation	NULL
.	NULL

Proc	NULL
Nat	NULL
!	NULL

Acad	NULL
Sci	NULL
USA	NULL
71:1	NULL
286	NULL
,	NULL
1974	NULL
23	NULL
.	NULL

Ley	NULL
KD	NULL
,	NULL
Tobey	NULL
RA	NULL
:	NULL
Regulation	NULL
of	NULL
initiation	NULL
of	NULL
DNA	NULL
synthesis	NULL
in	NULL
chinese	NULL
hamster	NULL
cells	NULL
.	NULL

J	NULL
Cell	NULL
Biol	NULL
47:453	NULL
,	NULL
1975	NULL
24	NULL
.	NULL

Brooks	NULL
RF	NULL
:	NULL
The	NULL
kinetics	NULL
of	NULL
serum-induced	NULL
initiation	NULL
of	NULL
DNA-synthesis	NULL
in	NULL
BHK	NULL
21/C13	NULL
cells	NULL
,	NULL
and	NULL
the	NULL
influence	NULL
of	NULL
exogenous	NULL
adenosine	NULL
.	NULL

J	NULL
Cell	NULL
Physiol	NULL
86:369	NULL
,	NULL
1975	NULL
25	NULL
.	NULL

Rossow	NULL
PW	NULL
,	NULL
Riddle	NULL
VGH	NULL
,	NULL
Pardee	NULL
AB	NULL
:	NULL
Synthesis	NULL
of	NULL
labile	NULL
serum-dependent	NULL
protein	NULL
in	NULL
early	NULL
G1	NULL
controls	NULL
animal	NULL
cell	NULL
growth	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
76:4446	NULL
,	NULL
1979	NULL
26	NULL
.	NULL

Croy	NULL
RG	NULL
,	NULL
Pardee	NULL
AB	NULL
:	NULL
Enhanced	NULL
synthesis	NULL
and	NULL
stabilization	NULL
of	NULL
Mr68,000	NULL
protein	NULL
in	NULL
transformed	NULL
BALB/c-3T3	NULL
cells	NULL
:	NULL
Candidate	NULL
for	NULL
restriction	NULL
point	NULL
control	NULL
of	NULL
cell	NULL
growth	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
80:4699	NULL
,	NULL
1983	NULL
27	NULL
.	NULL

Schwartz	NULL
SA	NULL
,	NULL
Morgenstern	NULL
B	NULL
,	NULL
Capizzi	NULL
RL	NULL
:	NULL
Schedule-dependent	NULL
synergy	NULL
and	NULL
antagonism	NULL
between	NULL
high-dose	NULL
1-	NULL
,	NULL
-D-arabinofura-nosylcytosine	NULL
and	NULL
asparaginase	NULL
in	NULL
the	NULL
L5178Y	NULL
murine	NULL
leukemia	NULL
.	NULL

Cancer	NULL
Res	NULL
42:2191	NULL
,	NULL
1982	NULL
28	NULL
.	NULL

Panasci	NULL
L	NULL
,	NULL
Polizzi	NULL
G	NULL
,	NULL
Palmer	NULL
S	NULL
:	NULL
Diminished	NULL
toxicity	NULL
of	NULL
methotrexate	NULL
in	NULL
CD	NULL
2	NULL
Fi	NULL
mice	NULL
pretreated	NULL
with	NULL
cycloheximide	NULL
.	NULL

Cancer	NULL
Lett	NULL
15:81	NULL
,	NULL
1982	NULL
29	NULL
.	NULL

Gorin	NULL
NC	NULL
:	NULL
Autologous	NULL
borne	NULL
marrow	NULL
transplantation	NULL
in	NULL
hematological	NULL
malignancies	NULL
.	NULL

Eur	NULL
J	NULL
Cancer	NULL
Clin	NULL
Oncol	NULL
20:1	NULL
,	NULL
1984	NULL
30	NULL
.	NULL

Ritz	NULL
J	NULL
,	NULL
Bast	NULL
RC	NULL
,	NULL
Claell	NULL
LA	NULL
,	NULL
Hercend	NULL
T	NULL
,	NULL
Sallan	NULL
SE	NULL
,	NULL
Lipton	NULL
JM	NULL
,	NULL
Feeney	NULL
M	NULL
,	NULL
Nathan	NULL
DJ	NULL
,	NULL
Schlossman	NULL
SF	NULL
:	NULL
Autologous	NULL
bone	NULL
marrow	NULL
transplantation	NULL
in	NULL
CALLA	NULL
positive	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
after	NULL
in	NULL
vitro	NULL
treatment	NULL
with	NULL
J5	NULL
monoclonal	NULL
antibody	NULL
and	NULL
complement	NULL
.	NULL

Lancet	NULL
2:60	NULL
,	NULL
1982	NULL
31	NULL
.	NULL

Sharkis	NULL
SJ	NULL
,	NULL
Santos	NULL
GW	NULL
,	NULL
Colvin	NULL
M	NULL
:	NULL
Elimination	NULL
of	NULL
acute	NULL
myelogenous	NULL
leukemia	NULL
cells	NULL
from	NULL
marrow	NULL
and	NULL
tumor	NULL
suspensions	NULL
in	NULL
the	NULL
rat	NULL
with	NULL
4-hydroperoxycyclophosphamide	NULL
.	NULL

Blood	NULL
55:521	NULL
,	NULL
1980	NULL
32	NULL
.	NULL

Kaizer	NULL
H	NULL
,	NULL
Tutschka	NULL
P	NULL
,	NULL
Stuart	NULL
R	NULL
,	NULL
Korbling	NULL
M	NULL
,	NULL
Braine	NULL
H	NULL
,	NULL
Saral	NULL
R	NULL
,	NULL
Colvin	NULL
M	NULL
,	NULL
Santos	NULL
G	NULL
:	NULL
Autologous	NULL
bone	NULL
marrow	NULL
transplantation	NULL
in	NULL
acute	NULL
leukemia	NULL
and	NULL
non-Hodgkin	NULL
's	NULL
lymphoma	NULL
:	NULL
A	NULL
phase	NULL
I	NULL
study	NULL
of	NULL
4-hydroperoxycyclophosphamide	NULL
(	NULL
4-HC	NULL
)	NULL
incubation	NULL
of	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

834	NULL
marrow	NULL
prior	NULL
to	NULL
cryopreservation	NULL
.	NULL

Hematol	NULL
Blood	NULL
Transfusion	NULL
28:90	NULL
,	NULL
1983	NULL
33	NULL
.	NULL

Young	NULL
CW	NULL
,	NULL
Dowling	NULL
MD	NULL
:	NULL
Antipyretic	NULL
effect	NULL
of	NULL
cycloheximide	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
protein	NULL
synthesis	NULL
,	NULL
in	NULL
patients	NULL
with	NULL
Hodgkin	NULL
's	NULL
disease	NULL
or	NULL
other	NULL
malignant	NULL
neoplasms	NULL
.	NULL

Cancer	NULL
Res	NULL
35:1	NULL
218	NULL
,	NULL
1975	NULL
34	NULL
.	NULL

Slevin	NULL
ML	NULL
,	NULL
Piall	NULL
EM	NULL
,	NULL
Aherne	NULL
GW	NULL
,	NULL
Johnston	NULL
A	NULL
,	NULL
Lister	NULL
TA	NULL
:	NULL
SLAPAK	NULL
,	NULL
FINE	NULL
,	NULL
AND	NULL
RICHMAN	NULL
The	NULL
clinical	NULL
pharmacology	NULL
of	NULL
cytosine	NULL
arabinoside	NULL
.	NULL

Hematol	NULL
Blood	NULL
Transfusion	NULL
28:70	NULL
,	NULL
1983	NULL
35	NULL
.	NULL

Spitzer	NULL
G	NULL
,	NULL
Verma	NULL
DS	NULL
,	NULL
Fisher	NULL
R	NULL
,	NULL
Zandor	NULL
A	NULL
,	NULL
Vellekoop	NULL
L	NULL
,	NULL
Litam	NULL
J	NULL
,	NULL
McCredie	NULL
KB	NULL
,	NULL
Dicke	NULL
KA	NULL
:	NULL
The	NULL
myeloid	NULL
progenitor	NULL
cell-its	NULL
value	NULL
in	NULL
predicting	NULL
hematopoietic	NULL
recovery	NULL
after	NULL
autologous	NULL
bone	NULL
marrow	NULL
transplantation	NULL
.	NULL

Blood	NULL
55:317	NULL
,	NULL
1980	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

blood	NULL
===	NULL
Differential	NULL
protection	NULL
of	NULL
normal	NULL
and	NULL
malignant	NULL
human	NULL
myeloid	NULL
progenitors	NULL
(	NULL
CFU-GM	NULL
)	NULL
from	NULL
Ara-C	NULL
toxicity	NULL
using	NULL
cycloheximide	NULL
CA	NULL
Slapak	NULL
,	NULL
RL	NULL
Fine	NULL
and	NULL
CM	NULL
Richman	NULL
4	NULL
_	NULL
5	NULL
,	NULL
'	NULL
_	NULL
>	NULL
,	NULL
#	NULL
04	NULL
;	NULL
©1004	NULL
@	NULL
207	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/66/4/830.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

